Eunice Kennedy Shriver National Institute of Child Health and Human Development

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, November 9, 2023

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.

Key Points: 
  • ET
    SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.
  • XACIATO™ provides a new therapeutic option for the millions of women suffering from bacterial vaginosis in the U.S.
  • Financial Highlights for the Quarter ended September 30, 2023
    Cash and cash equivalents: $13.8 million at September 30, 2023.
  • Daré will host a conference call and live webcast today, November 9, 2023, at 4:30 p.m. Eastern Time to review financial results for the quarter ended September 30, 2023 and to provide a company update.

New fertility research shows that IUDs do not reduce the number of eggs retrieved following ovarian stimulation

Retrieved on: 
Tuesday, October 17, 2023

Shady Grove Fertility's research team provides reassuring data that patients undergoing egg retrieval can keep IUDs.

Key Points: 
  • Shady Grove Fertility's research team provides reassuring data that patients undergoing egg retrieval can keep IUDs.
  • "Women who are considering fertility preservation are often worried about keeping their IUDs in place throughout the egg retrieval cycle," shares Phillip A. Romanski, M.D., M.Sc.
  • "Our research team was excited to learn that patients can rest assured they can keep their IUDs in place without worrying about the impact of eggs retrieved.
  • This important research can help many women take that next step toward preserving their fertility to help build their future family."

Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

Retrieved on: 
Tuesday, October 10, 2023

The lead author on this research is Wendy K. Chung, M.D., Ph.D., Division of Molecular Genetics, Department of Pediatrics, Columbia University, New York, NY.

Key Points: 
  • The lead author on this research is Wendy K. Chung, M.D., Ph.D., Division of Molecular Genetics, Department of Pediatrics, Columbia University, New York, NY.
  • Rhythm will post these data presentations on the Company’s website on the “Publications and Presentations” page following the conference.
  • This conference call will be accessible under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com .
  • A replay will be available on the Rhythm website for 30 days following the presentation.

UPDATE | Advanced imaging reveals altered brain chemistry of babies with congenital heart disease

Retrieved on: 
Monday, October 9, 2023

They found:

Key Points: 
  • They found:
    Those with CHD had higher levels of choline and lower levels of N-Acetyl aspartate-to-choline ratios compared to healthy babies, potentially representing disrupted brain development.
  • Babies with more complex CHD also had higher levels of cerebral lactate compared to babies with two ventricle CHD.
  • These critical heart defects generally require babies to undergo heart surgery not long after birth.
  • , chief of the Advanced Technologies and Surgery Branch in the Division of Cardiovascular Sciences at the National Heart, Lung and Blood Institute.

Advanced imaging reveals altered brain chemistry of babies with congenital heart disease

Retrieved on: 
Monday, October 9, 2023

They found:

Key Points: 
  • They found:
    Those with CHD had higher levels of choline and lower levels of N-Acetyl aspartate-to-choline ratios compared to healthy babies, potentially representing disrupted brain development.
  • Babies with more complex CHD also had higher levels of cerebral lactate compared to babies with two ventricle CHD.
  • These critical heart defects generally require babies to undergo heart surgery not long after birth.
  • , chief of the Advanced Technologies and Surgery Branch in the Division of Cardiovascular Sciences at the National Heart, Lung and Blood Institute.

Vanderbilt University establishes Roberts Academy and Dyslexia Center

Retrieved on: 
Tuesday, September 26, 2023

An unprecedented gift from Hal and Marjorie Hollis Roberts will establish a new academy for primary students with dyslexia and an innovative center focused on outreach and dyslexia research at Vanderbilt University.

Key Points: 
  • An unprecedented gift from Hal and Marjorie Hollis Roberts will establish a new academy for primary students with dyslexia and an innovative center focused on outreach and dyslexia research at Vanderbilt University.
  • View the full release here: https://www.businesswire.com/news/home/20230926550660/en/
    An unprecedented gift from Hal and Marjorie Hollis Roberts will establish a new academy for primary students with dyslexia and an innovative center focused on outreach and dyslexia research at Vanderbilt University.
  • The Roberts Academy and Dyslexia Center is the third academy for students with dyslexia funded by the Roberts and the first-of-its-kind research and outreach center established with their support.
  • These teachers will then take best practices from the Roberts Academy and Dyslexia Center into their classrooms throughout their careers.

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Retrieved on: 
Thursday, September 21, 2023

Under the terms of the grant agreement, Daré may receive a total of up to approximately $49 million to support nonclinical development of DARE-LARC1.

Key Points: 
  • Under the terms of the grant agreement, Daré may receive a total of up to approximately $49 million to support nonclinical development of DARE-LARC1.
  • Daré received an initial $11.5 million payment in 2021 and aggregate payments of approximately $12.4 million in 2022 under the grant agreement.
  • “The DARE-LARC1 product candidate is one of a number of novel contraceptive technologies being developed by Daré,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • Bayer, in its sole discretion, has the right to make the license effective by paying $20.0 million to Daré.

The FNIH Awards 2023 Charles A. Sanders, M.D., Partnership Award to NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, GSK, and the O’Neill Family

Retrieved on: 
Monday, September 18, 2023

The Foundation for the National Institutes of Health (FNIH) has named the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, GSK, and the O’Neill Family as recipients of the 2023 Charles A. Sanders, M.D., Partnership Award .

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) has named the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, GSK, and the O’Neill Family as recipients of the 2023 Charles A. Sanders, M.D., Partnership Award .
  • The Partnership Award recognizes persons or organizations that have made significant contributions to the FNIH’s work in support of the mission of the National Institutes of Health (NIH).
  • The Azithromycin Prevention in Labor Use Study (A-PLUS) assessed low-cost, sustainable interventions to improve maternal and child health.
  • The Charles A. Sanders, M.D., Partnership Award is named for the former Chairman of the FNIH Board of Directors.

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Retrieved on: 
Thursday, August 10, 2023

SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended June 30, 2023, and provided a company update.

Key Points: 
  • 2, 3
    A novel, investigational hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer HealthCare.
  • Financial Highlights for the Quarter ended June 30, 2023
    Cash and cash equivalents: $13.3 million at June 30, 2023.
  • Daré will host a conference call and live webcast today at 4:30 p.m. Eastern Time to review financial results for the quarter ended June 30, 2023 and to provide a company update.
  • The webcast and presentation slides will be archived under “Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com and available for replay until August 24, 2023.

Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

Retrieved on: 
Monday, July 31, 2023

SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it was awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) in the amount of approximately $385,000 to support activities related to the conduct and completion of proof-of-concept target validation studies in support of a potential new approach for the prevention and treatment of idiopathic preterm birth. Daré will collaborate with its sub awardee, the Lockwood Laboratory at the University of South Florida (USF) Morsani College of Medicine, on the grant-funded activities.

Key Points: 
  • SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it was awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) in the amount of approximately $385,000 to support activities related to the conduct and completion of proof-of-concept target validation studies in support of a potential new approach for the prevention and treatment of idiopathic preterm birth.
  • Daré will collaborate with its sub awardee, the Lockwood Laboratory at the University of South Florida (USF) Morsani College of Medicine, on the grant-funded activities.
  • Preterm birth is defined as a live birth before 37 completed weeks of gestation.1,2 Premature babies often have serious health problems.
  • March of Dimes PeriStats™, Preterm Birth, accessed 28 July 2023. https://www.marchofdimes.org/peristats/data?reg=99&slev=4&top=3